Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...
Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Eli Lilly (NYSE: LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...
Fintel reports that on December 15, 2025, B of A Securities maintained coverage of Eli Lilly and (NYSE:LLY) with a Buy ...
Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
The price target boosts come after LLY stock rose 30% during November amid a strong rally in the shares. The bull run comes ...
In this photo illustration, a Eli Lilly logo seen displayed on a smartphone. Eli Lilly’s stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally ...
Moreover, on November 24, Bernstein SocGen Group reiterated its Outperform rating on Eli Lilly & Company (NYSE:LLY) , with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback